Virpax Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Sendrow Jerrold, was filed 26 May 2022.
Virpax Pharmaceuticals, Inc.: what insiders have been doing
Virpax Pharmaceuticals, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Virpax Pharmaceuticals, Inc. has had no insider filing for more than a year; the last one goes back to 26 May 2022.
Since 2021, the database holds 7 purchases and no sales by insiders of the company.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Since the insiders bought
- -45.8%Entry US$357.50 · Close at T+365 US$193.75
- -36.9%Entry US$325.00 · Close at T+365 US$205.10
- -36.9%Entry US$325.00 · Close at T+365 US$205.10
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
- 4,500 shares@ US$1.2928.5% of flowCommon Stock, $0.00001 par valueSEC:0001493152-22-015224:0Canonical exit: 22 Aug 2022 (T+90)
- 4,479 shares@ US$1.3635100.0% of flowCommon Stock, $0.00001 par valueSEC:0001493152-22-014657:0Canonical exit: 16 Aug 2022 (T+90)
- 75,750 shares@ US$1.3452.3% of flowCommon Stock, $0.00001 par valueSEC:0001493152-22-014659:0Canonical exit: 16 Aug 2022 (T+90)
- 3,900 shares@ US$3.92571.5% of flowCommon Stock, $0.00001 par valueSEC:0000905718-21-001536:0Canonical exit: 20 Feb 2022 (T+90)
- 25,125 shares@ US$3.9947.7% of flowCommon Stock, $0.00001 par valueSEC:0000905718-21-001521:0Canonical exit: 16 Feb 2022 (T+90)
- 100 shares@ US$7.16Common Stock, $0.00001 par valueSEC:0001213900-21-012631:0Canonical exit: 18 May 2021 (T+90)
- 3,500 shares@ US$6.79100.0% of flowCommon Stock, $0.00001 par valueSEC:0001213900-21-010660:0Canonical exit: 18 May 2021 (T+90)
7 of 7 declarations
About Virpax Pharmaceuticals, Inc.
Virpax Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ in the United States (ticker: VRPX). Headquartered in Berwyn, Pennsylvania, the company was established and began operations in 2017. Virpax is still a preclinical-stage business with a limited operating history, which places it in the high-risk, development-stage segment of healthcare investing. Its valuation narrative depends heavily on scientific validation, regulatory progress, and access to capital rather than on current product sales. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1708331/000173112225000316/e6385_10k.htm?utm_source=openai))
Virpax’s core business is the development of proprietary drug-delivery systems and formulations aimed primarily at non-opioid pain management and certain central nervous system (CNS) disorders. The company highlights its Molecular Envelope Technology (MET) platform, which is designed to improve intranasal delivery and optimize how active ingredients reach their intended targets. Its pipeline includes Probudur for postoperative pain, Epoladerm for knee osteoarthritis, Envelta for severe pain, AnQlar as a potential antiviral barrier, and NobrXiol for select rare pediatric epilepsy indications. In practical terms, Virpax is a platform-driven pipeline company whose value proposition is built around differentiated delivery technology and unmet medical need. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1708331/000173112225000316/e6385_10k.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, Virpax operates in crowded therapeutic areas where large pharmaceutical companies, specialty biotechs, and generic drug-delivery developers compete for clinical data, intellectual property, and regulatory traction. Virpax attempts to stand out through non-addictive treatment concepts, novel formulations, and targeted routes of administration. The company has also referenced cooperative research and development agreements with U.S. government organizations, including the NIH and the Department of Defense, which can support development credibility and scientific collaboration. However, these arrangements do not eliminate the usual biotech risks tied to trial execution, FDA review, and financing. ([virpaxpharma.com](https://virpaxpharma.com/2024/05/13/virpax-pharmaceuticals-reports-2024-first-quarter-results-and-recent-developments/?utm_source=openai))
Geographically, Virpax’s operations are centered in the United States, with its corporate headquarters in Berwyn, Pennsylvania. Recent notable items include 2024 operating updates, financing announcements, and a reverse stock split disclosed in March 2025, all of which underscore the company’s ongoing capital-markets dependence. For investors in France, Belgium, and Switzerland, Virpax should be viewed as a speculative micro-cap biotech with an early-stage pipeline, a potentially differentiated technology stack, and a binary investment profile driven by development milestones, regulatory outcomes, and balance-sheet management. ([virpaxpharma.com](https://virpaxpharma.com/contact/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
